CN105535305A - Chinese patent medicine for treating sequelae of cerebral infarction and preparation method thereof - Google Patents
Chinese patent medicine for treating sequelae of cerebral infarction and preparation method thereof Download PDFInfo
- Publication number
- CN105535305A CN105535305A CN201511005175.2A CN201511005175A CN105535305A CN 105535305 A CN105535305 A CN 105535305A CN 201511005175 A CN201511005175 A CN 201511005175A CN 105535305 A CN105535305 A CN 105535305A
- Authority
- CN
- China
- Prior art keywords
- parts
- grams
- radix
- chinese patent
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of medicines and in particular relates to a Chinese patent medicine for treating sequelae of cerebral infarction, which can basically promote the recovery of the nerve functions of patients suffering from cerebral apoplexy hemiplegia, improve the living conditions of the patients and increase the living ability of the patients by taking multiple traditional Chinese medicinal materials as raw materials, as well as a preparation method thereof. The Chinese patent medicine is prepared from the following raw materials in parts by weight: 10-15 parts of prepared rehmannia root, 8-12 parts of morinda root, 10-15 parts of chuanxiong rhizome, 10-15 parts of leech, 4-10 parts of rhubarb, 8-12 parts of astragalus root, 8-12 parts of rhizoma acori graminei, 2-5 parts of borneol and 10-15 parts of talcum powder. The Chinese patent medicine is stable in medicine effect and directly acts on a focus through blood and blood vessels simultaneously to improve damaged brain cells and protect undamaged cells to create a favorable intracerebral environment, thereby achieving the effects of preventing thrombosis again and preventing the blood vessels from being clogged again by atheromatous plaque.
Description
Technical field
The invention belongs to pharmaceutical field, particularly relating to a kind of is that raw material can effective Chinese patent medicine for the treatment of cerebral infarction sequela and preparation method thereof with several kinds of Chinese medicinal materials.
Background technology
Cerebral infarction sequela refers generally to apoplexy sequela, apoplexy is the disease name of Chinese medicine, also be that people are to the general designation of acute cerebrovascular disease be commonly called as, primary disease is one group of disease being main clinical manifestation with cerebral ischemic and heamorrhagic lesions symptom, also known as apoplexy or cerebrovas-cularaccident, there is high case fatality rate and disability rate, be mainly divided into hemorrhagic cerebral apoplexy (cerebral hemorrhage or subarachnoid hemorrhage) and the large class of ischemia apoplexy (cerebral infarction, cerebral thrombosis) two.Hemorrhagic cerebral apoplexy Infant Mortality is very high, about has half patient dead within the morbidity a few days, most sequela such as the dyskinesia, cognitive disorder, speech dysphagia left in various degree in survivor.Ischemia apoplexy patient clinical is main sequela with hemiplegia.
Convalescent care is extremely important for cerebral infarction sequela patient, and traditional therapeutic modality, mainly based on conservative rehabilitation, comprises recovery function training and physical therapy.And why Cerebral Infarction Patients there will be hemiplegia, the sequela such as aphasis, occur the dysemias such as blood viscosity is high, blood fat is high, hypertension, platelet aggregation due to cerebral tissue inside, with vascular lesions such as atheromatous plaque formation, luminal stenosis, due to two kinds of coefficient results of pathological changes.Cause blood flow ceases and the necrosis of brain tissue ischemia anoxia of brain local, if have influence on the motorium nervous system controlled by cranial nerve, (divide the work from the cerebral hemisphere of people, right hemisphere manages left limb motion by motorium just to there will be the corresponding sequela such as hemiplegia; Left hemisphere, manages right side limb motion by nervus motorius.There is pathological changes in any side, all can cause contralateral hemiplegia).If it is neural to have influence on the speech center that cranial nerve controls, aphasis even corresponding neurological symptom and the sign such as aphasia will be caused.Want the generation, the reduction disease recurrence threat that effectively improve the sequela such as cerebral infarction hemiplegia, dysphonia; patient reasonable diet regulate and functional rehabilitation active with passive exercise while; by reliable Drug therapy; improve impaired brain cell; cell is not damaged in protection, and create a good brain environment, anti-tampon is formed again; the treatment means of atheromatous plaque artery-clogging again should be the key of cerebral infarction sequela Rehabilitation.
Western medicine cerebral infarction sequela have rapid-action, treat advantage targetedly, but action target spot is single, but most Western medicine can produce drug resistance, and the side effect of most Western medicine is obvious.Modern Chinese medicine can reach the object of simultaneously treating from blood and blood vessel, although most Chinese medicine onset is slow, but so for cerebral infarction sequela patient, based on Chinese Traditional Medicines, be aided with pointed western medicine, can efficacy enhancing and toxicity reducing be reached, the therapeutic purposes for the treatment of both the principal and secondary aspects of a disease, reach and effectively improve symptom, shorten the course of disease, prevent the multiple therapeutic effects recurred.
Summary of the invention
The object of the invention is to solve existing doctor trained in Western medicine single to treatment cerebral apoplexy sequela action target spot, easily make patient produce the high deficiency of the obvious and traditional recurrent only significantly do not caused for main curative effect with rehabilitation of drug resistance, side effect and a kind for the treatment of both the principal and secondary aspects of a disease, Chinese patent medicine for the treatment of cerebral infarction sequela of having no side effect and preparation method thereof be provided.
The object of the present invention is achieved like this:
Treat a Chinese patent medicine for cerebral infarction sequela, it is characterized in that: it is formed by the preparation of raw material of following portions by weight: Radix Rehmanniae Preparata 9 ~ 18 parts, Radix Morindae Officinalis 7 ~ 15 parts, Rhizoma Chuanxiong 9 ~ 18 parts, Hirudo 9 ~ 18 parts, Radix Et Rhizoma Rhei 3 ~ 12 parts, the Radix Astragali 7 ~ 15 parts, Rhizoma Acori Graminei 7 ~ 15 parts, Borneolum Syntheticum 1 ~ 6 part.
It is formed by the preparation of raw material of following portions by weight further: Radix Rehmanniae Preparata 10 ~ 15 parts, Radix Morindae Officinalis 8 ~ 12 parts, Rhizoma Chuanxiong 10 ~ 15 parts, Hirudo 10 ~ 15 parts, Radix Et Rhizoma Rhei 4 ~ 10 parts, the Radix Astragali 8 ~ 12 parts, Rhizoma Acori Graminei 8 ~ 12 parts, Borneolum Syntheticum 2 ~ 5 parts.
Concrete it is formed by the preparation of raw material of following portions by weight: Radix Rehmanniae Preparata 12 parts, Radix Morindae Officinalis 10 parts, Rhizoma Chuanxiong 12 parts, Hirudo 12 parts, Radix Et Rhizoma Rhei 6 parts, the Radix Astragali 10 parts, Rhizoma Acori Graminei 10 parts, Borneolum Syntheticum 3 parts.
A kind of preparation method for the treatment of the Chinese patent medicine of cerebral infarction sequela is as follows:
Step 1), get Radix Rehmanniae Preparata, Radix Morindae Officinalis, Rhizoma Chuanxiong, Hirudo, Radix Et Rhizoma Rhei, the Radix Astragali, Rhizoma Acori Graminei, Borneolum Syntheticum according to raw material weight number according to any one of claims 1 to 3, Radix Rehmanniae Preparata, Radix Morindae Officinalis, Rhizoma Chuanxiong, Hirudo, Radix Et Rhizoma Rhei, the Radix Astragali, Rhizoma Acori Graminei mixed powder are broken into fine powder, this fine powder is crossed 100 mesh sieves, obtain mixture of powders, Borneolum Syntheticum is pulverized borneol powder is separately deposited for subsequent use;
Step 2), gained mixture of powders in step 1 is adopted two lifting manipulation continuous circumfluence extraction, first time extracts and adds 8 times to the water of mixture of powders weight, second time is extracted and is added 6 times to the water of mixture of powders weight, employing electric jacket heats, then each extraction first maintains boiling 30 minutes with the low temperature of 150 ~ 200 degrees Celsius with the high temperature of 270 ~ 300 degrees Celsius is boiled, volatile oil extractor is adopted to extract volatile oil, obtained volatile oil is separately deposited for subsequent use, decocting liquid after extracted twice is merged and filters to obtain Aqueous extracts, Aqueous extracts is put into centrifuge with the centrifugation process of 4000 turns per minute, supernatant is obtained after centrifugal 15 minutes,
Step 3), to be put into by supernatant obtained in step 2 and revolve steaming instrument, evaporation removing moisture, obtaining extractum water content is 60%, and powdered extract obtains dry extract;
Step 4), dry extract described in step 3 is become fine powder with borneol powder described in step 1 by the weight ratio mixed grinding of 1:1, this fine powder is crossed 100 mesh sieves, obtains powder particle;
Step 5), powder particle obtained in step 4 and 95% ethanol are mixed and made into soft material by the Capacity Ratio of 1:3, with 14 mesh sieves, this soft material are extruded into granule, gained granule are spread out in ceramic whiteware dish, puts into baking box oven dry; In step 6), rate-determining steps 5 from the water content of baking box dry granule out 5%
Step 7), the Pulvis Talci of 3% of the dry granule obtained in step 6 and its weight to be mixed, by volatile oil obtained in step 2 with 95% ethanol mix by the Capacity Ratio of 1:4, obtain mixed liquor, this mixed liquor is sprayed into have been added in talcous dry granule, mix homogeneously, then do granulate process with 14 mesh sieves, tabletting after granulate, obtained sheet is heavily the tablet of 0.5g;
The present invention has the following advantages:
This various medical material of the present invention uses compatibility reasonable; through scientific method preparation, efficacy stability; dredging collateral is removed obstacles, warm invigorating kidney-YANG, blood-activating and qi-promoting, removing blood stasis, stasis removing, removing blood stasis dredging collateral, supplementing QI to prevent collapse, promoting the circulation of QI are had one's ideas straightened out, nourishing kidney yin; have and start with from blood and blood vessel simultaneously, through focus, improves impaired brain cell; cell is not damaged in protection; create a good brain environment, anti-tampon is formed again, effect of atheromatous plaque artery-clogging again.There is preparation technology's science, without any toxic and side effects, the advantage such as easy to use, effective to various types of cerebral infarction sequela through clinical verification, can be used for treating polytype cerebral infarction sequela.
The present invention has no side effect, and the medicine pharmacology in the formula adopted is: Radix Rehmanniae Preparata, sweet in the mouth, slightly warm in nature, return liver, kidney channel, have YIN nourishing of enriching blood, beneficial essence fills out effect of marrow, for blood deficiency and yellow complexion, severe palpitation, menoxenia, metrostaxis, the hepatic and renal YIN deficiency, soreness of the waist and knees, osteopyrexia and fever, night sweat is passed out semen, and interior-heat is quenched one's thirst, dizzy, tinnitus, chin is sent out early white; Radix Morindae Officinalis, sweet in the mouth, pungent, slightly warm in nature, returns kidney channel, Liver Channel, kidney-replenishing, bone and muscle strengthening, and for impotence and seminal emission, cold womb is infertile, menoxenia, young married woman's cold type of pain, rheumatism splenalgia, and muscles and bones is withered soft; Rhizoma Chuanxiong, acrid in the mouth, warm in nature, return liver, gallbladder, pericardium channel, blood-activating and qi-promoting, wind-expelling pain-stopping, for menoxenia, amenorrhea dysmenorrhea, lump in the abdomen is suffered from abdominal pain, costa sternales twinge, tumbling and swelling, headache, rheumatism splenalgia; Salty in the mouth, hardship, property is put down, slightly poisonous, returns Liver Channel, removing blood stasis, removing blood stasis, stimulates the menstrual flow for lump in the abdomen mass in the abdomen, blood stasis amenorrhea, injury from falling down; Radix Et Rhizoma Rhei, bitter in the mouth, cold in nature, return spleen, stomach, large intestine, pericardium channel, expel the heat-evil logical intestinal, removing pathogenic heat from blood and toxic substance from the body, eliminating blood stasis and inducing menstruation, for excess-heat constipation, stagnant stomachache, dysentery is not well, jaundice due to damp-heat, and heat in blood tells nosebleed, conjunctival congestion, pharyngeal swelling, abdominalgia with intestinal abscess, carbuncle furuncle, blood stasis amenorrhea, traumatic injury, external treatment burn due to hot liquid or fire; Upper gastrointestinal hemorrhage; The Radix Astragali, sweet in the mouth, warm in nature, return lung, spleen channel, invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation.Weak for the deficiency of vital energy, anorexia and loose stool, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, metrorrhagia of having blood in stool, exterior deficiency spontaneous perspiration, deficiency of vital energy edema, carbuncle difficulty is burst, and burst for a long time and do not hold back, blood deficiency dull yellowish colored skin, interior-heat is quenched one's thirst; Chronic nephritis proteinuria, diabetes; Rhizoma Acori Graminei, acrid in the mouth, hardship, warm in nature, GUIXIN, stomach warp, removing dampness is whetted the appetite, eliminating phlegm of having one's ideas straightened out, and refreshment Fructus Alpiniae Oxyphyllae is not hungry for gastral cavity painful abdominal mass, a mouthful dysentery of keeping silent, coma epilepsy, forgetful deafness; Borneolum Syntheticum, acrid in the mouth, hardship, cold nature, GUIXIN, spleen, lung meridian, refreshment of having one's ideas straightened out, clearing away heat to alleviate pain.Faint for calentura coma, convulsion, apoplexy syncope due to accumulation of phlegm, stagnation of QI sudden syncope, attacked by pestiferous factors is gone into a coma, and conjunctival congestion, aphtha, laryngopharynx swelling and pain, auditory meatus is suppurated.
Take a broad view of formula, all medicine compatibilities are reasonable, not only make " vital qi " to change source without cease, and " outpost of the tax office " can be made again in order closed, unblocked, sing altogether and open screen and open the strong merit of barrier, tissue regeneration promoting, Fang Zhong, Radix Rehmanniae Preparata nourishing kidney yin, the invigorating kidney-YANG of Radix Morindae Officinalis temperature, yin-yang match, regulation between water and fire is monarch drug altogether; Rhizoma Chuanxiong blood-activating and qi-promoting, Hirudo removing blood stasis, has the energy of " removing blood stasis with potent drugs blood and do not hinder fresh blood ", two medicines mutually 5, invigorates blood circulation and not hematozemia, and blood stasis dispelling again can tissue regeneration promoting, is ministerial drug altogether; Radix Et Rhizoma Rhei stasis removing, removing blood stasis dredging collateral, Radix Astragali supplementing QI to prevent collapse, two medicines share, and one anti-sending an expedition against too, two anti-ly invigorate blood circulation weak, is adjuvant drug altogether; Borneolum Syntheticum " fragrance is walked to alter, and priming is up ", Rhizoma Acori Graminei promoting the circulation of QI is had one's ideas straightened out; dredging collateral is removed obstacles; all medicines are led to go directly disease institute, altogether for making medicine, treating both the principal and secondary aspects of a disease; finally reach and improve impaired brain cell; cell is not damaged in protection, and create a good brain environment, anti-tampon is formed again; effect of atheromatous plaque artery-clogging again, effectively reduces disease relapse probability.
Below in conjunction with Clinical practice data, beneficial effect of the present invention is described:
Clinical experimental research
(1) impact that the Chinese patent medicine for the treatment of cerebral infarction sequela is expressed Patients with Cerebral Infarction TNF-ct, IL-1P
Object: the Chinese patent medicine inquiring into treatment cerebral infarction sequela changes cerebral infarction patient TNF-a, IL-13 level.
Method: adopt randomised study method, ischemic cerebral stroke patients 60 example meeting inclusion criteria is divided at random treatment group and each 30 routine patients of matched group.Matched group adopts western medicine routine treatment, and treatment group adopts the Chinese patent medicine of western medicine routine treatment Combined with Oral treatment cerebral infarction sequela.Within 15 days, be a course for the treatment of, treat 2 courses for the treatment of continuously.
Result: (1) treatment group is to the neurological deficits score reducing patient, and NIHSS scoring is all better than matched group, at Barthe index score, improvement Rankin scale (mRS) scoring aspect, contrasts no significant difference between two groups.In (2) two groups of patients serums, the content of TNF-a and IL-1P all has decline, more variant in group.
Conclusion: the Chinese patent medicine for the treatment of cerebral infarction sequela promotes to improve the recovery of stroke hemiplegia function of nervous system its animation, improve its viability.
(2) Chinese patent medicine of cerebral infarction sequela is treated to the research of cerebral ischemia-reperfusion injury in rats blood brain barrier Protective effects
Method: healthy male SD mouse is divided into sham operated rats, model group, medicine group by random digits table at random.Wherein, three groups are divided into 1d, 3d, 5d and 7d group according to the Reperfu-sion time.Prepare models of cerebral ischemia-reperfusion injury with right side middle cerebral artery line brush, acupuncture group is Baihui and the left tsusanli acupoint at the appointed time after modeling success; Medicine group is modeling success pneumoretroperitoneum injection Edaravone.After Reperfu-sion 7d, after each group rat anesthesia, broken end gets brain, calculates its cerebral infarction volume after TTC dyeing with ImageJ; Tunel method detects ischemic region brain tissue apoptosis situation.Application immunofluorescence observe MMP-2 (MMP-2), aquaporin 4 (AQP4) respectively with astrocyte and vascular endothelial cell coexpression situation; Each group of rat assesses rat functional impairment situation according to the Reperfu-sion time with the Neuroscore of improvement; Immunohistochemical staining and Westernblot method detect the expression of rats with cerebral ischemia MMP-2, AQP4, Occludin (Occludin), bifilar sealing albumen (CIaudin-5); Quantitative real-time PCR is adopted to detect the expression of rats with cerebral ischemia MMP-2, AQP4, ZO-1, Occludin;
Result: 1.TTC dyes display: sham operated rats can see the infarct of white, is formed contrast with cherry normal cerebral tissue.Medicine group rat cerebral infarction volume is lower than model group (P<0.05).2.TUNEL testing result shows: brown color dyeing is mainly expressed in karyon; Sham operated rats apoptotic cell percentage ratio is significantly lower than other each group (P<0.05); Medicine group apoptosis is lower than model group (P<0.05).3. neurologic impairment situation: mNSS marks display, and rats in sham-operated group cerebral tissue is without ischemia, and without limbs disturbance, scoring is 0 point; At each time point same period, the scoring of medicine group is all remarkable in model group (P<0.05).4. blood brain barrier index of correlation: the two dye display of (1) immunofluorescence, after cerebral ischemia reperfusion injury, MMP-2 and AQP4 mainly expresses at astrocyte foot and distributes along blood vessel endothelium; (2) MMP-2 is low expression in sham operated rats; The peak value of model group, medicine group is all at 5d, and compared with model group, the albumen of the MMP-2 of medicine group and the expression of mRNA all obviously reduce (P<0.05); (3) same period each time point; the albumen of medicine group ZO-1 and mRNA level in-site are higher than model group (P<0.05); (4) compared with model group, the expression of medicine group Claudin-5 albumen significantly raises (P<0.05); (5) AQP4 all becomes unimodal in the expression of model group, medicine group, and peak value is 3d, compared with model group the expression of AQP4 albumen and mRNA 5,7d time point significantly reduces (P<0.05.
Conclusion: 1. causing MMP-2, AQP4 and miRNA-29c of Blood Brain Barrier (BBB) permeability to express after cerebral ischemic reperfusion in rats increases, and ZO-1, Occludin, Claudin-5 and miRNA-320 of maintaining the metabolism of blood brain barrier koinomatter express and reduce.2. the Chinese patent medicine for the treatment of cerebral infarction sequela can lower the expression of MMP-2, AQP4 and miRNA-29c; Raise ZO-1, Occludin, Claudin-5 and miRNA-320 to express.3. the Chinese patent medicine for the treatment of cerebral infarction sequela can obviously improve cerebral ischemia-reperfusion injury in rats neurologic impairment, reduces cerebral infarction volume and apoptosis.
(3) Chinese patent medicine of cerebral infarction sequela is treated to the protective effect of MCAO/R rat model blood brain barrier and Mechanism Study
Method: line brush copies rat MCAO/R model, each treated animal is in cerebral ischemia 2h Reperfu-sion 24h, rat model is carried out to neurological scores, detects brain water content and cerebral tissue EB content, to evaluate the Chinese patent medicine for the treatment of cerebral infarction sequela to the protective effect of BBB; Neurological scores is carried out to rat model, detects cerebral tissue EB content, to evaluate the Chinese patent medicine for the treatment of cerebral infarction sequela to the protective effect of BBB.
Result: 1, compare with model group; the neurological that the Chinese patent medicine high (20mg/kg) for the treatment of cerebral infarction sequela, low (10mg/kg) dosage all obviously can improve rat model lacks symptom (P<0.01); and all obviously can reduce the EB content (P<0.001 and P<0.01) of rat model ischemia side cerebral tissue, show that the Chinese patent medicine for the treatment of cerebral infarction sequela has certain protective effect to BBB.2, compare with model group, the Chinese patent medicine high (105.27mg/kg) for the treatment of cerebral infarction sequela, low (11.397mg/kg) dosage group all obviously can reduce the disappearance of rat model ischemia side cerebral tissue Occludin, and difference has statistical significance (P<0.05); Rhizoma Gastrodiae EtOAc extract high dose (105.27mg/kg) group obviously can also be lowered rat model ischemia side cerebral tissue AQP-4 and expresses and reduce the disappearance of rat model ischemia side cerebral tissue Claudin-5, and difference has statistical significance (P<0.05 and P<0.01); And the expression of MMP-2, MMP-3 and MMP-9 is had to the trend of downward, but no significant difference.
Conclusion: the protective effect that the Chinese patent medicine for the treatment of cerebral infarction sequela has MCAO/R rat model blood brain barrier.
Detailed description of the invention
Embodiment 1: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 12 grams, Radix Morindae Officinalis 10 grams of parts, Rhizoma Chuanxiong 12 grams, Hirudo 12 grams, Radix Et Rhizoma Rhei 6 grams, the Radix Astragali 10 grams, Rhizoma Acori Graminei 10 grams, Borneolum Syntheticum 3 grams.
The preparation method of the Chinese patent medicine for the treatment of cerebral infarction sequela, its preparation method is as follows:
Step 1), get Radix Rehmanniae Preparata, Radix Morindae Officinalis, Rhizoma Chuanxiong, Hirudo, Radix Et Rhizoma Rhei, the Radix Astragali, Rhizoma Acori Graminei, Borneolum Syntheticum according to raw material weight number according to any one of claims 1 to 3, Radix Rehmanniae Preparata, Radix Morindae Officinalis, Rhizoma Chuanxiong, Hirudo, Radix Et Rhizoma Rhei, the Radix Astragali, Rhizoma Acori Graminei mixed powder are broken into fine powder, this fine powder is crossed 100 mesh sieves, obtain mixture of powders, Borneolum Syntheticum is pulverized borneol powder is separately deposited for subsequent use;
Step 2), gained mixture of powders in step 1 is adopted two lifting manipulation continuous circumfluence extraction, first time extracts and adds 8 times to the water of mixture of powders weight, second time is extracted and is added 6 times to the water of mixture of powders weight, employing electric jacket heats, then each extraction first maintains boiling 30 minutes with the low temperature of 150 ~ 200 degrees Celsius with the high temperature of 270 ~ 300 degrees Celsius is boiled, volatile oil extractor is adopted to extract volatile oil, obtained volatile oil is separately deposited for subsequent use, decocting liquid after extracted twice is merged and filters to obtain Aqueous extracts, Aqueous extracts is put into centrifuge with the centrifugation process of 4000 turns per minute, supernatant is obtained after centrifugal,
Step 3), to be put into by supernatant obtained in step 2 and revolve steaming instrument, evaporation removing moisture, obtaining extractum water content is 60%, and powdered extract obtains dry extract;
Step 4), dry extract described in step 3 is become fine powder with borneol powder described in step 1 by the weight ratio mixed grinding of 1:1, this fine powder is crossed 100 mesh sieves, obtains powder particle;
Step 5), powder particle obtained in step 4 and 95% ethanol are mixed and made into soft material by the Capacity Ratio of 1:3, with 14 mesh sieves, this soft material are extruded into granule, gained granule are spread out in ceramic whiteware dish, puts into baking box oven dry;
In step 6), rate-determining steps 5 from the water content of baking box dry granule out 5%, obtain dry granule
Step 7), the Pulvis Talci of 3% of the dry granule obtained in step 6 and its weight to be mixed, by volatile oil obtained in step 2 with 95% ethanol mix by the Capacity Ratio of 1:4, obtain mixed liquor, this mixed liquor is sprayed into have been added in talcous dry granule, mix homogeneously, then do granulate process with 14 mesh sieves, tabletting after granulate, obtained sheet is heavily the tablet of 0.5g;
Embodiment 2: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 18 grams, Radix Morindae Officinalis 15 grams of parts, Rhizoma Chuanxiong 18 grams, Hirudo 18 grams, Radix Et Rhizoma Rhei 12 grams, the Radix Astragali 15 grams, Rhizoma Acori Graminei 15 grams, Borneolum Syntheticum 6 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 3: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 10 grams, Radix Morindae Officinalis 8 grams, Rhizoma Chuanxiong 10 grams, Hirudo 10 grams, Radix Et Rhizoma Rhei 4 grams, the Radix Astragali 8 grams, Rhizoma Acori Graminei 8 grams, Borneolum Syntheticum 2 grams, follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 4: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 15 grams, Radix Morindae Officinalis 12 grams, Rhizoma Chuanxiong 15 grams, Hirudo 15 grams, Radix Et Rhizoma Rhei 10 grams, the Radix Astragali 12 grams, Rhizoma Acori Graminei 12 grams, Borneolum Syntheticum 5 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 5: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 9 grams, Radix Morindae Officinalis 7 grams, Rhizoma Chuanxiong 9 grams, Hirudo 9 grams, Radix Et Rhizoma Rhei 3 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 7 grams, Borneolum Syntheticum 1 gram.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 6: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 13.5 grams, Radix Morindae Officinalis 11 grams of parts, Rhizoma Chuanxiong 12 grams, Hirudo 12 grams, Radix Et Rhizoma Rhei 6 grams, the Radix Astragali 10 grams, Rhizoma Acori Graminei 10 grams, Borneolum Syntheticum 4 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 7: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 16 grams, Radix Morindae Officinalis 13 grams of parts, Rhizoma Chuanxiong 15 grams, Hirudo 16 grams, Radix Et Rhizoma Rhei 10.5 grams, the Radix Astragali 13 grams, Rhizoma Acori Graminei 13.5 grams, Borneolum Syntheticum 5 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 8: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 12 grams, Radix Morindae Officinalis 7 grams of parts, Rhizoma Chuanxiong 9 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 8.5 grams, Borneolum Syntheticum 3 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 9: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 12 grams, Radix Morindae Officinalis 11 grams of parts, Rhizoma Chuanxiong 11 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 9 grams, Rhizoma Acori Graminei 13.5 grams, Borneolum Syntheticum 2 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 10: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 9 grams, Radix Morindae Officinalis 10 grams of parts, Rhizoma Chuanxiong 11 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 6 grams, the Radix Astragali 9 grams, Rhizoma Acori Graminei 15 grams, Borneolum Syntheticum 6 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 11: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 9 grams, Radix Morindae Officinalis 13 grams of parts, Rhizoma Chuanxiong 9 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 10 grams, Borneolum Syntheticum 3 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 12: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 9 grams, Radix Morindae Officinalis 13 grams of parts, Rhizoma Chuanxiong 15 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 8.5 grams, Borneolum Syntheticum 3 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 13: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 13.5 grams, Radix Morindae Officinalis 7 grams of parts, Rhizoma Chuanxiong 12 grams, Hirudo 14, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 8.5 grams, Borneolum Syntheticum 3 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 14: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 12 grams, Radix Morindae Officinalis 15 grams of parts, Rhizoma Chuanxiong 9 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 8.5 grams, Borneolum Syntheticum 3 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 15: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 12 grams, Radix Morindae Officinalis 7 grams of parts, Rhizoma Chuanxiong 17 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 8.5 grams, Borneolum Syntheticum 3 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 16: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 12 grams, Radix Morindae Officinalis 7 grams of parts, Rhizoma Chuanxiong 9 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 13.5 grams, Borneolum Syntheticum 3 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 17: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 9 grams, Radix Morindae Officinalis 7 grams of parts, Rhizoma Chuanxiong 18 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 8.5 grams, Borneolum Syntheticum 1 gram.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 18: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 12 grams, Radix Morindae Officinalis 10 grams, Rhizoma Chuanxiong 9 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 9 grams, Rhizoma Acori Graminei 8.5 grams, Borneolum Syntheticum 3 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 19: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 12 grams, Radix Morindae Officinalis 7 grams of parts, Rhizoma Chuanxiong 9 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 15 grams, Rhizoma Acori Graminei 8.5 grams, Borneolum Syntheticum 3 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 20: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 16 grams, Radix Morindae Officinalis 11 grams of parts, Rhizoma Chuanxiong 9 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 15 grams, Borneolum Syntheticum 4 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 21: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 16 grams, Radix Morindae Officinalis 11 grams of parts, Rhizoma Chuanxiong 9 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 8.5 grams, Borneolum Syntheticum 3 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 22: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 16 grams, Radix Morindae Officinalis 11 grams of parts, Rhizoma Chuanxiong 18 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 8.5 grams, Borneolum Syntheticum 3 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 23: the Chinese patent medicine for the treatment of cerebral infarction sequela is formed by the preparation of raw material of following weight: Radix Rehmanniae Preparata 16 grams, Radix Morindae Officinalis 11 grams of parts, Rhizoma Chuanxiong 17 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 8.5 grams, Borneolum Syntheticum 3 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 24: treatment cerebral infarction sequela Chinese patent medicine be formed by the preparation of raw material of following weight:, Radix Rehmanniae Preparata 16 grams, Radix Morindae Officinalis 11 grams of parts, Rhizoma Chuanxiong 17 grams, Hirudo 14 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 8.5 grams, Borneolum Syntheticum 3 grams.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Embodiment 25: treatment cerebral infarction sequela Chinese patent medicine be formed by the preparation of raw material of following weight:, Radix Rehmanniae Preparata 16 grams, Radix Morindae Officinalis 7 grams of parts, Rhizoma Chuanxiong 17 grams, Hirudo 10.5 grams, Radix Et Rhizoma Rhei 5 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 7 grams, Borneolum Syntheticum 1 gram.Follow-up concrete preparation method is consistent with embodiment 1, no longer repeats herein.
Case:
Leading case 1: patient Chen Zuwang, man, 60 years old, people from Foochow, Fujian, patient's identification number: 23807, on August 12nd, 2013 was chief complaint is admitted to hospital with " dysphagia 4 years ".Occurred dizzy before 4 years without obvious inducement, hoarseness, dysphagia, drinking-water is choked and is coughed, and accompany left limb unable, go to a doctor in Affiliated Hospital of Medical University Of Fujian first, be diagnosed as cerebral infarction, unable through treatment (concrete medicine for treatment is not quite clear) limbs of patient, the symptoms such as hoarseness are left hospital after taking a turn for the better, but patient's dysphagia has no obvious improvement, row on March 17 " Ponsky method " in 2011, postoperative stoma inbutation feeding liquid, for asking further dysphagia therapeutic, spy comes my institute and seeks medical advice.Give Radix Rehmanniae Preparata 9 grams, Radix Morindae Officinalis 7 grams of parts, Rhizoma Chuanxiong 9 grams, Hirudo 9 grams, Radix Et Rhizoma Rhei 3 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 7 grams, Borneolum Syntheticum 1 gram, be decocted in water for oral dose, one day potion, day takes twice.Each 400 milliliters, be used in conjunction February, and after coordinating ice fire therapy two course of therapy, patient can the food such as a small amount of Fructus Musae of oral feeding, egg custard, follow up a case by regular visits to 6 months without exception.
Leading case 2: patient Chen Ling, female, 54 years old, Liaoning people from Yingkou City, patient's identification number: 23944, on October 15th, 2014 was to be chief complaint with " aphasia, dysphagia January ".Suddenly occurred that dizziness, aphasia, drinking-water were choked and coughed without obvious inducement before January, right side limb activity is unfavorable, companion's Nausea and vomiting, no headache, blurred vision, deliver to local hospital to seek medical advice, look into head B-sonography to show: brain stem infarct, multiple lacunar infarction, concrete medicine for treatment is not quite clear, and above-mentioned symptom is left hospital after taking a turn for the better, leave over aphasia, dysphagia, indwelling nasal feeding tube, for asking further treatment, spy comes my institute and seeks medical advice.Give Radix Rehmanniae Preparata 9 grams, Radix Morindae Officinalis 7 grams of parts, Rhizoma Chuanxiong 9 grams, Hirudo 9 grams, Radix Et Rhizoma Rhei 3 grams, the Radix Astragali 7 grams, Rhizoma Acori Graminei 7 grams, Borneolum Syntheticum 1 gram, be decocted in water for oral dose, one day potion, day takes twice.Each 400 milliliters, be used in conjunction January and after coordinating ice fire therapy to treat two courses for the treatment of, patient successfully pulls out nasal feeding tube, and oral feeding can meet nutrition supply, follow up a case by regular visits to 6 months without exception.
Claims (5)
1. treat a Chinese patent medicine for cerebral infarction sequela, it is characterized in that: it is formed by the preparation of raw material of following portions by weight: Radix Rehmanniae Preparata 9 ~ 18 parts, Radix Morindae Officinalis 7 ~ 15 parts, Rhizoma Chuanxiong 9 ~ 18 parts, Hirudo 9 ~ 18 parts, Radix Et Rhizoma Rhei 3 ~ 12 parts, the Radix Astragali 7 ~ 15 parts, Rhizoma Acori Graminei 7 ~ 15 parts, Borneolum Syntheticum 1 ~ 6 part.
2. treat a Chinese patent medicine for cerebral infarction sequela, it is characterized in that: it is formed by the preparation of raw material of following portions by weight: Radix Rehmanniae Preparata 10 ~ 15 parts, Radix Morindae Officinalis 8 ~ 12 parts, Rhizoma Chuanxiong 10 ~ 15 parts, Hirudo 10 ~ 15 parts, Radix Et Rhizoma Rhei 4 ~ 10 parts, the Radix Astragali 8 ~ 12 parts, Rhizoma Acori Graminei 8 ~ 12 parts, Borneolum Syntheticum 2 ~ 5 parts.
3. treat a Chinese patent medicine for cerebral infarction sequela, it is characterized in that: it is formed by the preparation of raw material of following portions by weight: Radix Rehmanniae Preparata 12 parts, Radix Morindae Officinalis 10 parts, Rhizoma Chuanxiong 12 parts, Hirudo 12 parts, Radix Et Rhizoma Rhei 6 parts, the Radix Astragali 10 parts, Rhizoma Acori Graminei 10 parts, Borneolum Syntheticum 3 parts.
4. treat a preparation method for the Chinese patent medicine of cerebral infarction sequela, it is characterized in that: its preparation method is as follows:
Step 1), get Radix Rehmanniae Preparata, Radix Morindae Officinalis, Rhizoma Chuanxiong, Hirudo, Radix Et Rhizoma Rhei, the Radix Astragali, Rhizoma Acori Graminei, Borneolum Syntheticum according to raw material weight number according to any one of claims 1 to 3, Radix Rehmanniae Preparata, Radix Morindae Officinalis, Rhizoma Chuanxiong, Hirudo, Radix Et Rhizoma Rhei, the Radix Astragali, Rhizoma Acori Graminei mixed powder are broken into fine powder, this fine powder is crossed 100 mesh sieves, obtain mixture of powders, Borneolum Syntheticum is pulverized borneol powder is separately deposited for subsequent use;
Step 2), gained mixture of powders in step 1 is adopted two lifting manipulation continuous circumfluence extraction, first time extracts and adds 8 times to the water of mixture of powders weight, second time is extracted and is added 6 times to the water of mixture of powders weight, employing electric jacket heats, then each extraction first maintains boiling 30 minutes with the low temperature of 150 ~ 200 degrees Celsius with the high temperature of 270 ~ 300 degrees Celsius is boiled, volatile oil extractor is adopted to extract volatile oil, obtained volatile oil is separately deposited for subsequent use, decocting liquid after extracted twice is merged and filters to obtain Aqueous extracts, Aqueous extracts is put into centrifuge with the centrifugation process 15 minutes of 4000 turns per minute, supernatant is obtained after centrifugal,
Step 3), to be put into by supernatant obtained in step 2 and revolve steaming instrument, evaporation removing moisture, obtain extractum, extractum water content is 60%, and powdered extract obtains dry extract;
Step 4), dry extract described in step 3 is become fine powder with borneol powder described in step 1 by the weight ratio mixed grinding of 1:1, this fine powder is crossed 100 mesh sieves, obtains powder particle;
Step 5), powder particle obtained in step 4 and 95% ethanol are mixed and made into soft material by the Capacity Ratio of 1:3, with 14 mesh sieves, this soft material are extruded into granule, gained granule are spread out in ceramic whiteware dish, puts into baking box oven dry;
Be 5% from the water content of baking box dry granule out in step 6), rate-determining steps 5, obtain dry granule;
Step 7), the Pulvis Talci of 3% of the dry granule obtained in step 6 and its weight to be mixed, by volatile oil obtained in step 2 with 95% ethanol mix by the Capacity Ratio of 1:4, obtain mixed liquor, this mixed liquor is sprayed into have been added in talcous dry granule, mix homogeneously, then do granulate process with 14 mesh sieves, tabletting after granulate, obtained sheet is heavily the tablet of 0.5g.
5. a kind of preparation method for the treatment of the Chinese patent medicine of cerebral infarction sequela according to claim 4, it is characterized in that, the pressure in described step 5 in baking box is 0.1MPA, and the temperature in baking box is 20 degrees Celsius.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511005175.2A CN105535305A (en) | 2015-12-29 | 2015-12-29 | Chinese patent medicine for treating sequelae of cerebral infarction and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511005175.2A CN105535305A (en) | 2015-12-29 | 2015-12-29 | Chinese patent medicine for treating sequelae of cerebral infarction and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105535305A true CN105535305A (en) | 2016-05-04 |
Family
ID=55815216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511005175.2A Pending CN105535305A (en) | 2015-12-29 | 2015-12-29 | Chinese patent medicine for treating sequelae of cerebral infarction and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105535305A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110693986A (en) * | 2019-11-15 | 2020-01-17 | 陕西中医药大学附属医院 | A Chinese medicinal composition for external application on acupuncture point for treating dysphagia, and its preparation method |
| CN111588792A (en) * | 2020-05-27 | 2020-08-28 | 张金生 | Chinese patent medicine for treating dysphagia after stroke |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101279018A (en) * | 2008-05-28 | 2008-10-08 | 山东沃华医药科技股份有限公司 | Chinese medicine naoxueshu preparations |
-
2015
- 2015-12-29 CN CN201511005175.2A patent/CN105535305A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101279018A (en) * | 2008-05-28 | 2008-10-08 | 山东沃华医药科技股份有限公司 | Chinese medicine naoxueshu preparations |
Non-Patent Citations (1)
| Title |
|---|
| 王筠默等: "《中药研究与文献检索》", 30 September 1994, 上海远东出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110693986A (en) * | 2019-11-15 | 2020-01-17 | 陕西中医药大学附属医院 | A Chinese medicinal composition for external application on acupuncture point for treating dysphagia, and its preparation method |
| CN111588792A (en) * | 2020-05-27 | 2020-08-28 | 张金生 | Chinese patent medicine for treating dysphagia after stroke |
| CN111588792B (en) * | 2020-05-27 | 2021-11-30 | 张金生 | Chinese patent medicine for treating dysphagia after stroke |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101095923B (en) | Chinese traditional medicine for treating ectopic pregnancy | |
| CN104524335A (en) | Pill for conditioning female endocrine disorders and preparation method of pill | |
| CN103920034A (en) | Traditional Chinese medicine composition for alleviating side effects of chemotherapy of cancer patient and preparation method traditional Chinese medicine composition | |
| CN101342357B (en) | Chinese medicinal composition for treating gland hyperplasia and preventing and controlling mammary cancer | |
| CN102847074B (en) | Blood stasis removing pill for treating ankylosing spondylitis | |
| CN102552793A (en) | Chinese medicinal composition for treating unstable angina pectoris derived from aged coronary heart disease | |
| CN102008674B (en) | Plaster for treating herniated disk, hyperosteogeny and rheumatoid diseases and preparation method thereof | |
| CN104623376B (en) | Be used for the treatment of prosopalgic medicine | |
| CN105535305A (en) | Chinese patent medicine for treating sequelae of cerebral infarction and preparation method thereof | |
| CN103202985B (en) | Traditional Chinese medicine used for treating lumbar spondylosis, cervical spondylosis, sciatica and rheumatism and preparation method thereof | |
| CN104225490A (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN103690799B (en) | A kind of Chinese medicine preparation for the treatment of cerebral infarction | |
| CN104800610A (en) | Traditional Chinese medicine preparation for treating Parkinson's disease and preparation method thereof | |
| CN105233208A (en) | Traditional Chinese medicine preparation for treating heart failure | |
| CN104435641A (en) | Traditional Chinese medicine preparation for treating hyperthyroidism | |
| CN104758754A (en) | Medicine for treating kidney qi deficiency benign prostate hyperplasia and preparation method thereof | |
| CN104055900A (en) | Traditional Chinese medicine composition for treating urticaria | |
| CN103610772A (en) | Traditional Chinese medicine for treating cerebral thrombosis | |
| CN102872210B (en) | Traditional Chinese medicine for treating urticaria | |
| CN105213885A (en) | A kind of pharmaceutical composition and application thereof for the treatment of acute pancreatitis | |
| CN106266989A (en) | A kind of Chinese medicine composition for treating caused by energy stagnation and blood stasis hysteromyoma | |
| CN105770293A (en) | Oral traditional Chinese medicine preparation for treating fever | |
| CN104940777A (en) | Electuary capable of treating liver-yang hyperactivity and spleen weakness type diarrhea during menstruation and preparation method thereof | |
| CN105749170A (en) | Oral traditional Chinese medicine preparation for treating acute fever | |
| CN104225506A (en) | Medicinal preparation for treating thrombocytopenia after chemotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160504 |